Primary prevention and delay of onset of AD/dementia (Q36806653)

16 August 2017

1 reference

title

Primary prevention and delay of onset of AD/dementia (English)

1 reference

16 August 2017

Howard H Feldman

1

1 reference

PubMed ID

17469689

16 August 2017

Claudia Jacova

series ordinal

2

1 reference

16 August 2017

1 March 2007

1 reference

Canadian Journal of Neurological Sciences

16 August 2017

1 reference

16 August 2017

34 Suppl 1

1 reference

16 August 2017

S84-9

1 reference

Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study

16 August 2017

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

Statins and the risk of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

Pharmacotherapy for Alzheimer's disease: 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

Current concepts in mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

Current concepts in the prevention of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

An active and socially integrated lifestyle in late life might protect against dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

Hormone therapy and risk of Alzheimer disease: a critical time.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

Hippocampal formation glucose metabolism and volume losses in MCI and AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

Rates of hippocampal atrophy correlate with change in clinical status in aging and AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

Prevalence and severity of cognitive impairment with and without dementia in an elderly population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

Aging, mild cognitive impairment, and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

Folate and homocysteine metabolism: therapeutic targets in cardiovascular and neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

Treatment with simvastatin in patients with Alzheimer's disease lowers both alpha- and beta-cleaved amyloid precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

Designing a large prevention trial: statistical issues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

The GuidAge study: methodological issues. A 5-year double-blind randomized trial of the efficacy of EGb 761 for prevention of Alzheimer disease in patients over 70 with a memory complaint

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

Participation in cognitively stimulating activities and risk of incident Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

Leisure activities and the risk of dementia in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

Mental Work Demands Protect Against Cognitive Impairment: MAAS Prospective Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

Correlates of nonparticipation in the Canadian Study of Health and Aging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

inferred from DOI database lookup

7 January 2021

based on heuristic

A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

inferred from DOI database lookup

7 January 2021

based on heuristic

Neuropathological criteria for the diagnosis of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1017%2FS0317167100005631

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1017/S0317167100005631

1 reference

16 August 2017

1 reference

PubMed ID

17469689